Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis Group, a generic pharmaceuticals company, has gained FDA approval for Ropinirole extended-release tablets, 2mg, 4mg, 6mg, 8mg and 12mg.
Subscribe to our email newsletter
The company has started distribution of the generic version of GlaxoSmithKline’s Requip XL.
Actavis CEO Doug Boothe said, "The launch of Ropinirole Extended-Release Tablets showcases Actavis’ commitment in bringing new products to market to benefit both patients and payors. We are proud to play a part in lowering healthcare costs through the introduction of quality generic products."
According to IMS Health, Requip XL, 2mg, 4mg, 6mg, 8mg and 12mg, had US sales of approximately $59.4m for the 12 months ending 31 December 2011.